Document is current
Any future updates will be listed below
-
Authors
Schweickart, Annalise
Batra, Richa
Neth, Bryan J.
Martino, Cameron
Shenhav, Liat
Zhang, Anru R.
Shi, Pixu
Karu, Naama
Huynh, Kevin
Meikle, Peter J.
Schimmel, Leyla
Dilmore, Amanda Hazel
Blennow, Kaj
Zetterberg, Henrik
Blach, Colette
Dorrestein, Pieter C.
Knight, Rob
,
Craft, Suzanne
Kaddurah-Daouk, Rima
Krumsiek, Jan
-
Funding
Funding for this research was provided by:
National Institute on Aging (U19AG063744, U19AG063744, U19AG063744, U19AG063744, U19AG063744, U19AG063744, U19AG063744, U19AG063744, U19AG063744, U19AG063744, U19AG063744, U19AG063744, U19AG063744, U19AG063744, U19AG063744, U19AG063744, U19AG063744, U19AG063744, U19AG063744, U19AG063744, U19AG063744)
Alzheimer”s Association (AARFD-22-974775, AARFD-22-974775)
Alzheimer”s Disease Research Center, Wake Forest School of Medicine (P30AG049638)
National Center for Advancing Translational Sciences (UL1TR001420)
Foundation for the National Institutes of Health (DAOU16AMPA)
- License Information
-
More Information
Article History
Received: 16 January 2024
Accepted: 16 May 2024
First Online: 1 July 2024
Competing interests
: P.C.D. consulted for DSM animal health in 2023, is an advisor and holds equity in Cybele, bileOmix and Sirenas, and a Scientific co-founder, advisor and holds equity in Ometa, Enveda, and Arome with prior approval by UC San Diego. K.B. has served as a consultant and on advisory boards for Abbvie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served on data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper.
